Clinician's perspectives on gene therapy for Alzheimer's disease: A qualitative study.
| dc.contributor.author | Kelemen, Lilly | |
| dc.contributor.author | Gupta, Ishika | |
| dc.contributor.author | Yavarow, Zollie | |
| dc.contributor.author | Smith, Samantha I | |
| dc.contributor.author | Johnson, Kim G | |
| dc.contributor.author | Boucher, Nathan A | |
| dc.contributor.editor | Ginsberg, Stephen D | |
| dc.date.accessioned | 2025-02-02T13:33:58Z | |
| dc.date.available | 2025-02-02T13:33:58Z | |
| dc.date.issued | 2024-01 | |
| dc.description.abstract | IntroductionWe aimed to understand clinician views regarding gene therapy as a future treatment for Alzheimer's disease (AD) and potential barriers and facilitators to its use.MethodsWe interviewed ten clinicians who treat patients with AD. Clinicians helped design a semi-structured interview including the following domains: establishing understanding, cost/access, quality of life, and religion/spirituality. Transcripts were analyzed by a coding team using descriptive content analysis with inductive approach.ResultsClinicians identified three main areas of concern: 1) potential clinician and patient understanding of gene therapy and Alzheimer's disease 2) consideration of inequity (i.e., care access, disease awareness along with education level, family support, trust in care systems); and 3) considerations in decision-making (i.e., religious/spiritual beliefs and method of treatment delivery as a decision-making tools).Discussion and conclusionFindings highlight areas for knowledge-building for patients and clinicians alike. Clinicians must be aware of patient/family educational needs and gaps in their own clinical knowledge before engaging patients/families with new technology. Allowing time for questions is crucial to building rapport and trust. | |
| dc.identifier | PONE-D-24-09705 | |
| dc.identifier.issn | 1932-6203 | |
| dc.identifier.issn | 1932-6203 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Public Library of Science (PLoS) | |
| dc.relation.ispartof | PloS one | |
| dc.relation.isversionof | 10.1371/journal.pone.0307567 | |
| dc.rights.uri | ||
| dc.subject | Humans | |
| dc.subject | Alzheimer Disease | |
| dc.subject | Attitude of Health Personnel | |
| dc.subject | Health Knowledge, Attitudes, Practice | |
| dc.subject | Decision Making | |
| dc.subject | Qualitative Research | |
| dc.subject | Quality of Life | |
| dc.subject | Adult | |
| dc.subject | Middle Aged | |
| dc.subject | Female | |
| dc.subject | Male | |
| dc.subject | Genetic Therapy | |
| dc.title | Clinician's perspectives on gene therapy for Alzheimer's disease: A qualitative study. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Johnson, Kim G|0000-0002-8793-2489 | |
| duke.contributor.orcid | Boucher, Nathan A|0000-0002-5732-1927 | |
| pubs.begin-page | e0307567 | |
| pubs.issue | 7 | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | Sanford School of Public Policy | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | School of Nursing | |
| pubs.organisational-group | Nursing | |
| pubs.organisational-group | Basic Science Departments | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Medicine | |
| pubs.organisational-group | Psychiatry & Behavioral Sciences | |
| pubs.organisational-group | Medicine, Geriatrics and Palliative Care | |
| pubs.organisational-group | University Initiatives & Academic Support Units | |
| pubs.organisational-group | Neurology | |
| pubs.organisational-group | Neurology, Behavioral Neurology | |
| pubs.organisational-group | Initiatives | |
| pubs.organisational-group | Population Health Sciences | |
| pubs.organisational-group | Psychiatry & Behavioral Sciences, Adult Psychiatry & Psychology | |
| pubs.organisational-group | Duke-Margolis Institute for Health Policy | |
| pubs.publication-status | Published | |
| pubs.volume | 19 |
Files
Original bundle
- Name:
- Clinicians perspectives on gene therapy for Alzheimers disease A qualitative study.pdf
- Size:
- 403.16 KB
- Format:
- Adobe Portable Document Format